Susan J Little

Jan 16, 2025 | nature.com | Bo Zhang |Shiyu Chen |Nadine Rouphael |Angela R. Branche |David J. Diemert |Daniel S. Graciaa | +15 more

AbstractNeutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic’s evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate’s contemporary performance.

Mar 11, 2024 | nature.com | Craig A Magaret |Allan C. deCamp |Morgane Rolland |Michal Juraska |Brian Williamson |James Ludwig | +23 more

AbstractIn the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe–critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs.

Sep 22, 2023 | journals.plos.org | Seth C Inzaule |Amsterdam UMC |Mark J. Siedner |Susan J Little

Loading metrics Open Access Policy Forum Policy Forum articles provide a platform for health policy makers from around the world to discuss the challenges and opportunities in improving health care to their constituencies. See all article types » Citation: Inzaule SC, Siedner MJ, Little SJ, Avila-Rios S, Ayitewala A, Bosch RJ, et al. (2023) Recommendations on data sharing in HIV drug resistance research. PLoS Med 20(9): e1004293.

Aug 28, 2023 | nature.com | Angela R. Branche |David J. Diemert |Susan J Little |Evan Anderson |Angelica C. Kottkamp |Anne F. Luetkemeyer | +19 more

AbstractVaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized clinical trial with sequentially enrolled stages at 22 US sites, we assessed safety and immunogenicity of a second boost with monovalent or bivalent variant vaccines from mRNA and protein-based platforms targeting wild-type, Beta, Delta and Omicron BA.1 spike antigens.